These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33517512)

  • 41. Problems with NICE's severity weights.
    Hausman DM
    Soc Sci Med; 2024 May; 348():116833. PubMed ID: 38636210
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Influence of Cost-Effectiveness and Other Factors on Nice Decisions.
    Dakin H; Devlin N; Feng Y; Rice N; O'Neill P; Parkin D
    Health Econ; 2015 Oct; 24(10):1256-1271. PubMed ID: 25251336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Searching for cost effectiveness thresholds in the NHS.
    Appleby J; Devlin N; Parkin D; Buxton M; Chalkidou K
    Health Policy; 2009 Aug; 91(3):239-45. PubMed ID: 19168255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
    Brown P; Calnan M
    Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic evaluation and decision making in the UK.
    Buxton MJ
    Pharmacoeconomics; 2006; 24(11):1133-42. PubMed ID: 17067197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care.
    Chalkidou K; Lord J; Obeidat NA; Alabbadi IA; Stanley AG; Bader R; Momani A; O'Mahony RM; Qatami L; Cutler D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):151-8. PubMed ID: 21473813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The ethics of grandfather clauses in healthcare resource allocation.
    Wester G; Gibson Rand LZ; Lu C; Sheehan M
    Bioethics; 2021 Feb; 35(2):151-160. PubMed ID: 33043477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is the QALY blind, deaf and dumb to equity? NICE's considerations over equity.
    Soares MO
    Br Med Bull; 2012; 101():17-31. PubMed ID: 22331197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. National Institute for Health and Clinical Excellence: the Medical Technologies Evaluation Programme.
    J Med Eng Technol; 2011 Jul; 35(5):283-4. PubMed ID: 21635177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are the UK systems of innovation and evaluation of medical devices compatible? The role of NICE's Medical Technologies Evaluation Programme (MTEP).
    Chapman AM; Taylor CA; Girling AJ
    Appl Health Econ Health Policy; 2014 Aug; 12(4):347-57. PubMed ID: 24934924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs.
    Shin G; Kwon HY; Bae S
    Int J Environ Res Public Health; 2022 Apr; 19(7):. PubMed ID: 35409887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
    Chen G; Peirce V; Marsh W
    Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Review of Economic Models Submitted to NICE's Technology Appraisal Programme, for Treatments of T1DM & T2DM.
    Daly MJ; Elvidge J; Chantler T; Dawoud D
    Front Pharmacol; 2022; 13():887298. PubMed ID: 35645790
    [No Abstract]   [Full Text] [Related]  

  • 55. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Consultation on changes to technology appraisals.
    Nurs Manag (Harrow); 2016 Dec; 23(8):11. PubMed ID: 27905247
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The NHS: assessing new technologies, NICE and value for money.
    Stevens A; Chalkidou K; Littlejohns P
    Clin Med (Lond); 2011 Jun; 11(3):247-50. PubMed ID: 21902077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
    Kaltenthaler E; Papaioannou D; Boland A; Dickson R
    Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.